Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 17 studies | 31% ± 12% | |
| peripheral blood | 16 studies | 32% ± 12% | |
| intestine | 10 studies | 25% ± 10% | |
| eye | 8 studies | 26% ± 12% | |
| kidney | 6 studies | 22% ± 5% | |
| brain | 6 studies | 28% ± 10% | |
| liver | 6 studies | 28% ± 15% | |
| bone marrow | 4 studies | 23% ± 6% | |
| uterus | 4 studies | 32% ± 15% | |
| breast | 4 studies | 26% ± 2% | |
| lymph node | 4 studies | 28% ± 8% | |
| pancreas | 3 studies | 49% ± 24% | |
| placenta | 3 studies | 31% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 6004.24 | 1445 / 1445 | 100% | 48.48 | 183 / 183 |
| intestine | 100% | 6319.39 | 966 / 966 | 100% | 58.25 | 527 / 527 |
| kidney | 100% | 6535.63 | 89 / 89 | 100% | 37.62 | 901 / 901 |
| liver | 100% | 4754.49 | 226 / 226 | 100% | 40.68 | 406 / 406 |
| ovary | 100% | 5528.72 | 180 / 180 | 100% | 78.07 | 430 / 430 |
| pancreas | 100% | 4463.29 | 328 / 328 | 100% | 57.64 | 178 / 178 |
| prostate | 100% | 6604.26 | 245 / 245 | 100% | 77.68 | 502 / 502 |
| skin | 100% | 6577.26 | 1809 / 1809 | 100% | 79.18 | 472 / 472 |
| stomach | 100% | 5300.07 | 359 / 359 | 100% | 50.85 | 286 / 286 |
| thymus | 100% | 8347.07 | 653 / 653 | 100% | 73.01 | 605 / 605 |
| uterus | 100% | 5586.68 | 170 / 170 | 100% | 69.81 | 459 / 459 |
| brain | 100% | 6194.50 | 2640 / 2642 | 100% | 52.52 | 705 / 705 |
| lung | 100% | 6744.68 | 578 / 578 | 100% | 59.20 | 1154 / 1155 |
| breast | 100% | 7000.54 | 459 / 459 | 100% | 63.84 | 1114 / 1118 |
| bladder | 100% | 5663.48 | 21 / 21 | 99% | 65.11 | 500 / 504 |
| adrenal gland | 100% | 6177.82 | 258 / 258 | 99% | 39.94 | 228 / 230 |
| adipose | 100% | 6692.25 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 175.19 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 74.15 | 29 / 29 |
| muscle | 100% | 8967.79 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 7740.05 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 57.08 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 75.76 | 1 / 1 |
| blood vessel | 100% | 4911.15 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| heart | 100% | 4875.53 | 859 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 99% | 5808.80 | 918 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0180010 | Biological process | co-transcriptional mRNA 3'-end processing, cleavage and polyadenylation pathway |
| GO_0006369 | Biological process | termination of RNA polymerase II transcription |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0005847 | Cellular component | mRNA cleavage and polyadenylation specificity factor complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0008420 | Molecular function | RNA polymerase II CTD heptapeptide repeat phosphatase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0017018 | Molecular function | myosin phosphatase activity |
| Gene name | SSU72 |
| Protein name | RNA polymerase II subunit A C-terminal domain phosphatase SSU72 (CTD phosphatase SSU72) (EC 3.1.3.16) |
| Synonyms | HSPC182 PNAS-120 |
| Description | FUNCTION: Protein phosphatase that catalyzes the dephosphorylation of the C-terminal domain of RNA polymerase II. Plays a role in RNA processing and termination. Plays a role in pre-mRNA polyadenylation via its interaction with SYMPK. . |
| Accessions | ENST00000359060.5 [Q9NP77-2] Q9NP77 ENST00000291386.4 [Q9NP77-1] |